- Joined
- Dec 26, 2006
- Messages
- 7,100
- Reaction score
- 17,534
No doubt drug development is expensive. But how much of that development is the taxpayer directly or indirectly subsidizing?The problem is that the drug companies will argue, "Would you rather have 1970s drugs at 1970s prices? or 2020s drugs at 2020s prices?"
The argument is not without totally without merit. Research, development, clinical trials, risks of liability, etc. cost a fortune. If you want to lessen the reward for success, you need to look at the cost of failure. That said, drug company margins are pretty fat compared to most industries.
In this cross-sectional study of 356 drugs approved by the US Food and Drug Administration from 2010 to 2019, the NIH spent $1.44 billion per approval on basic or applied research for products with novel targets or $599 million per approval considering applications of basic research to multiple products.
Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019
How does National Institutes of Health (NIH) investment in pharmaceutical innovation compare with investment by the pharmaceutical industry?In this cross-sectional study of 356 drugs approved by the US Food and Drug Administration from 2010 to 2019, the ...
www.ncbi.nlm.nih.gov